Loading
IRF4 is a master transcription factor of plasma cells and a protein myeloma cells cannot do without. Lenalidomide and its successors lower IRF4 by destroying the two factors, Ikaros and Aiolos, that keep it switched on.
IRF4 (chromosome 6p25.3) is a transcriptional activator that binds the interferon-stimulated response element of the MHC class I promoter and, with PU.1, the immunoglobulin lambda light-chain enhancer; it acts in lymphoid-specific signalling and, in complex with the BATF-JUNB heterodimer at AICE elements, in CD8 dendritic-cell differentiation (UniProt Q15306). In OnCo it is the downstream node of the immunomodulatory drugs: lenalidomide and golcadomide degrade Ikaros and Aiolos through cereblon, IRF4 and MYC fall, and the myeloma cell dies (lenalidomide mechanism steps).
In plain words · IRF4 is a master transcription factor of plasma cells and a protein myeloma cells cannot do without. Lenalidomide and its successors lower IRF4 by destroying the two factors, Ikaros and Aiolos, that keep it switched on.
IRF4 is a master transcription factor of plasma cells and a protein myeloma cells cannot do without. Lenalidomide and its successors lower IRF4 by destroying the two factors, Ikaros and Aiolos, that keep it switched on.
IRF4 is not bound by any corpus drug; it is lowered as a consequence of Ikaros and Aiolos degradation, which is why it sits at the end of the immunomodulatory drug mechanism alongside MYC.
No product in this corpus aims at IRF4 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1996. Earliest sequence paper UniProt cites for the protein: Grossman et al, Genomics, 1996, "Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25". Source.
IRF4 is not bound by any corpus drug; it is lowered as a consequence of Ikaros and Aiolos degradation, which is why it sits at the end of the immunomodulatory drug mechanism alongside MYC.
Query for this target: (TITLE:"IRF4" OR ABSTRACT:"IRF4" OR TITLE:"MUM1" OR ABSTRACT:"MUM1" OR TITLE:"LSIRF" OR ABSTRACT:"LSIRF" OR TITLE:"interferon regulatory factor 4" OR ABSTRACT:"interferon regulatory factor 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IRF4, not a curated reading list.
Shares Transcriptional machinery & addiction, MYC and the tag wave5-target.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag wave5-target.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag wave5-target.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag wave5-target.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag wave5-target.
Shares Diffuse large B-cell lymphoma and the tag wave5-target.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag wave5-target.
Shares Diffuse large B-cell lymphoma and the tag wave5-target.